

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FIRST-NAMED INVENTOR: Shimkets

FOR: Novel Nucleic Acid Sequences Encoding Human Semaphorin-like

Polypeptides

**Assistant Commissioner for Patents** Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT AND ACCOMPANYING **FORM PTO-1449**

Applicants submit herewith copies of modified PTO-1449 forms submitted in parent application USSN 09/604,286 from which the presently filed application claims priority. Copies of the references listed therein are not enclosed but will be provided upon request. Applicants request that each of the listed documents be made of record in the presently filed application.

This information disclosure statement is being submitted concurrently with the filing of the application. Accordingly, no fee is believed due. However, the Commissioner is authorized to charge any fees due, or credit overpayments of same, to Deposit Account No. 50-0311, Ref. No. 15966-554 CON-S14 (Cura-54 CON-S14).

Respectfully submitted,

Dated: November 2, 2001

Ivor R. Elrifi, Reg. No. 39,529 Naomi S. Biswas, Reg. No. 38,384 Attorneys for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241 Express Mail No.: EK611852822US Date of Deposit: September 11, 2000

Please type a plus sign (+) in this box +

Attorney Docket No.: 15966-554

PTO/SB (12-97)
Approved for use through 9/30/00, OMB 0651-0031
ent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	raicht and 11a	BEHALL OTTE: U.S. DETARTMENT OF CONDITIONE
Modified Form 1449/PTO	Application Number	09/604,286
	Filing Date	6/22/00
INFORMATION DISCLOSURE	First Named Inventor	Shimkets
STATEMENT BY APPLICANT	Group Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
(use as many sheets as necessary)	Attorney Docket Number	15966-554

				U.S. PATENT DOCUMENTS			
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,597,725	1/28/97	Suzuki, S.			

Exam Initials	1 11 -		gn Patent Document Number	Name of Faccinee(s) of Applicant(s)		Transl Yes	ation No
	B1	wo	99/61471	Tang, Y.T.	12/2/99		
	B2	wo	99/53051	Edwards, D.M.	10/21/99		
	B3	wo	99/31236	Bougueleret, L.	6/24/99		
	B4	wo	86/04239	Shoyab, M	7/31/86		

	37.73	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CI	Genbank Accession Number: P31044
	C2	Genbank Accession Number: P30086
	C3	Genbank Accession Number: Q13670
	C4	Genbank Accession Number: 075631
	C5	Genbank Accession Number: P79995
	C6	Genbank Accession Number: P55285
	C7	Genbank Accession Number: 000276
	C8	Genbank Accession Number: Q64151
	C9	Genbank Accession Number: Q92854
	C10	Genbank Accession Number: P07106
	CII	Hall, K. T., L. Boumsell, et al. (1996). "Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation." <i>Proc Natl Acad Sci U S A</i> 93(21): 11780-5.
	C12	Nicolaides, N. C., K. C. Carter, et al. (1995). "Genomic organization of the human PMS2 gene family." Genomics 30(2): 195-206.
	C13	Wu, X. R. and T. T. Sun (1993). "Molecular cloning of a 47 kDa tissue-specific and differentiation-dependent urothelial cell surface glycoprotein." J. Cell. Sci. 106(Pt 1): 31-43.

Examiner Signature	Date Considered		
-----------------------	--------------------	--	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRADEDOCS:1357824



Express Mail No.: EL870248065US Date of Deposit: August 2, 2001

Please type a plus sign (+) in this box

1	7
1	1

Attorney Docket No.: 15966-554

Modified Form 1449/PTO	Application Number	09/604,286
	Filing Date	6/22/00
INFORMATION DISCLOSURE	First Named Inventor	Shimkets
STATEMENT BY APPLICANT	Group Art Unit	1632
	Examiner Name	R. Schnizer
(use as many sheets as necessary)	Attorney Docket Number	15966-554

1,6., 1.							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A2	5,888,742	3/30/99	Lal et al.			
*	А3	5,011,777	4/30/91	Shoyab et al.			
	A4	5,646,250	7/8/97	Suzuki			

		, <u> </u>					
Exam Initials	Cite For		n Patent Document	FOREIGN PATENT DOCUMENTS  Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B5	wo	99/06550	Genetics Institute Inc.	2/11/99		
	B6	wo	99/02546	Human Genome Sciences Inc.	1/21/99		
	B7	wo	97/17368	Dana Farber Cancer Institute	5/15/97		
~-	88	wo	98/45712	Human Genome Sciences Inc.	10/15/98		
	В9	wo	97/07198	Genectics Institute Inc.	2/27/97		
	B10	wo	99/05256	Harvard College	2/4/99		
	B11	wo	00/09552	Genetics Institute Inc.	2/24/00		

il.		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C14	Marra et al., "Stragene mouse heart (#937316) Mus musculus cDNA clone." EMBL Accession Number: AA089062, 1996.
	C15	Hillier et al., "Soares infant brain 1NIB Homo sapiens cDNA clone." EMBL Accession Number: H18553, 1995.
	C16	Strausberg R., "NCI_CGAP_GC6 Homo sapiens cDNA clone." EMBL Accession Number: Al638881, 1999.
	C17	Hillier et al., "Soares melanocyte 2NbHM Homo sapiens cDNA clone." EMBL Accession Number: W01259, 1996.
	C18	Fushimi et al., "Cloning and expression analysis of cadherin-10 in the CNS of the chicken embryo." Developmental Dynamics 209:269-85, 1997.
	C19	Kools et al., "The human cadherin-10 gene: complete coding sequence, predominant expression in the brain, and mapping on chromosome 5p13-14." FEBS Lett 452:328-34, 1999.
	C20	Inagaki et al., "Identification of a member of mouse semaphorin family." FEBS Lett 370:269-72, 1995.

	Examiner Signature	Date Considered	
1	Signature	 Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.